[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"news-article-aurora-accuses-curaleaf-of-pressuring-shareholders-as-official-takeover-bid-launches-6d25d076":3},{"data":4},{"_id":5,"slug":6,"articleType":7,"body":8,"createdAt":17,"dek":18,"entities":19,"headline":39,"imageAlt":40,"imageUrl":41,"keyFacts":42,"language":62,"publishedAt":63,"seo":64,"sources":67,"summary":72,"updatedAt":73},"6a9097fcaeddfad21a39f9d4","aurora-accuses-curaleaf-of-pressuring-shareholders-as-official-takeover-bid-launches-6d25d076","m_and_a",[9,10,11,12,13,14,15,16],"Curaleaf Holdings formally launched its unsolicited takeover bid for Aurora Cannabis on August 18, 2026, giving Aurora shareholders until December 1, 2026 to decide whether to tender their shares.","The offer combines 0.3463 of a Curaleaf share and US$0.75 in cash for each Aurora share, together worth US$4.00, representing a 45% premium to Aurora's unaffected 30-day volume-weighted price of US$2.75, or 110% once Aurora's cash pile is stripped out.","Aurora's board has formed a special committee of independent directors and urged shareholders to take no action before it makes a formal recommendation, expected within 15 days of the bid's launch, around September 2.","Aurora CEO Miguel Martin accused Curaleaf of making its offer public to pressure shareholders into a short-term decision for the benefit of Curaleaf shareholders, stating that Curaleaf's objective is to acquire Aurora's EU-GMP facilities and medical cannabis platforms at the lowest price possible.","Curaleaf's Boris Jordan defended the bid price by citing significant headwinds for Aurora in Canada and Germany, including the cancellation of German medical cannabis reimbursement and reduced Canadian medical cannabis reimbursement rates.","For the deal to close, more than half of Aurora's shareholders need to agree to sell, not counting Curaleaf's own stake, and at least two-thirds of Aurora's shares overall, including potential share conversions, must be tendered under Canadian rules.","Curaleaf says there is no financing or due-diligence condition attached to the offer, only regulatory approvals and standard closing terms, including that Aurora's shareholder rights plan, if adopted, must not interfere.","On the same day as the bid launch, Aurora announced a £2.1 million acquisition of Internode Pharma and HAP Pharma, a licensed importer and pharmacy in Birmingham, giving it direct ownership of the UK supply chain from import through to patient dispensing.","2026-08-27T20:03:08.543Z","Curaleaf has formally launched its unsolicited bid for Aurora Cannabis, setting a December 1 deadline while Aurora urges shareholders to take no action.",{"brands":20,"products":23,"markets":24,"organizations":28},[21,22],"Curaleaf","Aurora Cannabis",[],[25,26,27],"Canada","Germany","UK",[29,22,30,31,32,33,34,35,36,37,38],"Curaleaf Holdings","Prohibition Partners","Zuanic & Associates","Torys LLP","Stikeman Elliott","Paul, Weiss","Fort Capital Partners","Kingsdale Advisors","Internode Pharma","HAP Pharma","Aurora Accuses Curaleaf of Pressuring Shareholders as Official Takeover Bid Launches","Curaleaf and Aurora Cannabis corporate logos side by side, representing the unsolicited takeover bid.","",[43,47,50,53,56,59],{"claim":44,"sourceUrl":45,"_id":46},"Curaleaf formally launched its takeover bid for Aurora Cannabis on August 18, 2026, with the offer open until December 1, 2026.","https:\u002F\u002Fbusinessofcannabis.com\u002Faurora-accuses-curaleaf-of-pressuring-shareholders-as-it-launches-official-takeover-bid\u002F","6a9097fce81f0249cd72d42b",{"claim":48,"sourceUrl":45,"_id":49},"Curaleaf's offer combines 0.3463 of a Curaleaf share and US$0.75 in cash for each Aurora share, together worth US$4.00, a 45% premium to Aurora's unaffected 30-day volume-weighted price.","6a9097fce81f0249cd72d42c",{"claim":51,"sourceUrl":45,"_id":52},"Aurora's board has urged shareholders to take no action before it makes a formal recommendation, expected within 15 days of the bid's launch.","6a9097fce81f0249cd72d42d",{"claim":54,"sourceUrl":45,"_id":55},"Aurora CEO Miguel Martin accused Curaleaf of making its offer public to pressure shareholders into making a short-term decision for the benefit of Curaleaf shareholders.","6a9097fce81f0249cd72d42e",{"claim":57,"sourceUrl":45,"_id":58},"The bid values Aurora at roughly US$236 million on a basic-share basis, though that could change once outstanding options and warrants are counted.","6a9097fce81f0249cd72d42f",{"claim":60,"sourceUrl":45,"_id":61},"Aurora announced a £2.1 million acquisition of Internode Pharma and HAP Pharma, giving it direct ownership of the UK supply chain from import through to patient dispensing.","6a9097fce81f0249cd72d430","en","2026-08-28T05:26:14.544Z",{"title":65,"description":66},"Aurora Accuses Curaleaf of Pressuring Shareholders","Curaleaf launches official takeover bid for Aurora Cannabis, offering US$4.00 per share. Aurora urges shareholders to take no action pending review.",[68],{"name":69,"url":45,"trustTier":70,"_id":71},"Business of Cannabis","trade","6a9097fce81f0249cd72d42a","Curaleaf Holdings has submitted an official takeover bid for Aurora Cannabis, offering 0.3463 Curaleaf shares plus US$0.75 cash per Aurora share, valued at roughly US$236 million. Aurora's board has told shareholders to take no action pending a formal recommendation expected around September 2, while CEO Miguel Martin accused Curaleaf of pressuring shareholders into a short-term decision.","2026-08-28T05:26:14.629Z"]